{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:03:26Z","timestamp":1793016206866,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cmi.2023.05.028","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T12:41:47Z","timestamp":1685018507000},"page":"1188-1195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study"],"prefix":"10.1016","volume":"29","author":[{"given":"Anselm","family":"Jorda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ristl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Radner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sieghart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.05.028_bib1","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2048559","article-title":"The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study","volume":"18","author":"Jubishi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2023.05.028_bib2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.vaccine.2022.02.025","article-title":"Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine","volume":"40","author":"Tani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2023.05.028_bib3","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.4110\/in.2021.21.e41","article-title":"Correlation between reactogenicity and immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccination","volume":"21","author":"Lim","year":"2021","journal-title":"Immune Netw"},{"key":"10.1016\/j.cmi.2023.05.028_bib4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.cmi.2022.07.002","article-title":"Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses","volume":"28","author":"Braun","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.05.028_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.37908","article-title":"Association of symptoms after COVID-19 vaccination with anti-SARS-CoV-2 antibody response in the Framingham Heart Study","volume":"5","author":"Hermann","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2023.05.028_bib6","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3390\/vaccines10101608","article-title":"Association between adverse reactions and humoral immune response no longer detectable after BNT162b2 booster vaccination","volume":"10","author":"Bauernfeind","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2023.05.028_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jiac.2022.09.012","article-title":"Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model","volume":"29","author":"Matsumoto","year":"2023","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2023.05.028_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cmi.2022.12.008","article-title":"Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers","volume":"29","author":"Radner","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.05.028_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.03149-20","article-title":"Quantitative measurement of Anti-SARS-CoV-2 antibodies: analytical and clinical evaluation","volume":"59","author":"Higgins","year":"2021","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.05.028_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/clinchem\/hvaa198","article-title":"Side-by-Side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity","volume":"66","author":"Perkmann","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.cmi.2023.05.028_bib11","series-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.cmi.2023.05.028_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/011542650802300176","article-title":"Biostatistics primer: Part 2","volume":"23","author":"Overholser","year":"2008","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.cmi.2023.05.028_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2023.05.028_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-022-00453-5","article-title":"Use of analgesics\/antipyretics in the management of symptoms associated with COVID-19 vaccination","volume":"7","author":"Ooi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.cmi.2023.05.028_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.794642","article-title":"Reactogenicity and immunogenicity of the pfizer and AstraZeneca COVID-19 vaccines","volume":"12","author":"Mahallawi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2023.05.028_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s43856-022-00216-2","article-title":"Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions","volume":"2","author":"Li","year":"2022","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.cmi.2023.05.028_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00915-21","article-title":"Correlation of immunogenicity and reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 vaccines","volume":"7","author":"Zhang","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.cmi.2023.05.028_bib18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/vaccines9101063","article-title":"Reactogenicity correlates only weakly with humoral immunogenicity after COVID-19 vaccination with BNT162b2 mRNA (Comirnaty\u00ae)","volume":"9","author":"Held","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2023.05.028_bib19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2023.05.028_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2023.05.028_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cmi.2023.05.028_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/cid\/ciab465","article-title":"Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients","volume":"74","author":"Ogata","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.05.028_bib23","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of\u00a0protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:35:50Z","timestamp":1761118550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1198743X23002525"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.05.028","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}